What You Should Know:
- Ubie, Inc., a Tokyo-based healthcare startup, announced it has closed its Series C round at $45M by raising $19M in an extension round. The new funding will enable Ubie to accelerate its growth and strengthen its presence in the U.S., following strong interest and traction in that market. To date, Ubie has raised $76 million in total.
- With AI as its core technology, Ubie provides AI symptom checker Ubie as the gateway to medical care. It will also focus on
Read More
Startups| Digital Health | | Health IT News, Analysis, Insights - HIT Consultant
Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs
What You Should Know:
- Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.
- Vevo is the first platform to make in vivo data generation scalable with single-cell precision + will create the world’s largest atlas of how drugs interact with patient cells. In a single in vivo
Read More
CrowdHealth Secures $6M for Community-Powered Alternative to Health Insurance
What You Should Know:
- CrowdHealth recently secured $6 million in Series A funding from Next Coast Ventures and Activate Venture Partners. CrowdHealth plans to reinvest that funding back into the company—growing the CrowdHealth community and providing more tools for members that want to take charge of their healthcare and affordably break free from health insurance.
- Operating under a monthly membership model, CrowdHealth is a healthcare technology company that offers a new way to
Read More
Digital Health VCs Cite ROI & Clinical Validation As Greatest Markers of Company’s Success
What You Should Know:
- Investors in the healthcare technology space believe a measurable return on investment (ROI) and clinical validation of the technology's platform will be the greatest indicators of company success in 2023, according to a new survey of top digital health investors by GSR Ventures.
- ROI was deemed "important" or "very important" to the success of digital health companies by more than 94% of investor respondents, and 79% for clinical evidence and trials.
Top
Read More
UpStream Raises $140M to Expand Value-Based Care Model Nationwide
What You Should Know:
- Value-based care provider UpStream raises $140M in Series B funding co-led by Coatue and Dragoneer with additional participation from other top healthcare and technology investors, including Avidity Partners, Define Ventures and Mubadala. This round brings its total funding to nearly $185M to date.
- UpStream supports physicians operating under full-risk, value-based arrangements who are providing care to seniors on Medicare with an integrated platform that
Read More
Lumen Raises $62M for Handheld Device to Measure Metabolic Health
What You Should Know:
- Lumen, the metabolic health company behind the first handheld device to measure your metabolism through the breath, today announced that it has raised $62M in a series B funding round led by Pitango Venture Capital.
- Participating investors include Hanwha Group, Resolute Ventures, RiverPark Ventures, Unorthodox Ventures, Almeda Capital, and Disruptive VC.
World’s Largest Platform For Measuring Metabolism To Expand Business Growth and Research
Lumen helps
Read More
UCLA Spinout PictorLabs Launches with $18.8M to Revolutionize Histopathology
What You Should Know:
- PictorLabs launches with more than $18M in financing to advance an AI-powered virtual staining platform to revolutionize histopathology, an area that has seen little change in over a century and is essential for clinical research and patient diagnoses. Investors include M Venture (Merck's corporate VC arm), SSC Soft Computer, and Koç Holding.
- Spun out of UCLA, PictorLabs replaces complex chemical-based tissue staining processes (which are time-consuming to
Read More
Nectin Therapeutics Raises $25M for Immuno-Oncology Therapies
What You Should Know:
- Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immune-oncology treatments, announced it has extended its Series A financing to over $25 million. IBF and Peregrine Ventures led the round, with participation from aMoon Fund and other existing investors.
- The funding will be used to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of
Read More
Rgenta Therapeutics Raises $52M for Integrative RNA-Targeting Discovery Platform
What You Should Know:
- Rgenta Therapeutics Inc. raises a $52M Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital.
- Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets.
Targeting the “Undruggables”
Only a quarter of the proteins implicated in human diseases are currently druggable by traditional
Read More
Eyenovia Secures $15M for Ophthalmic Drug Delivery Technologies
What You Should Know:
- Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company enters a $15M credit facility with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”).
- The financing is
Read More
